Zykadia may now be used as a first-line treatment for patients with metastatic non-small cell lung cancer whose tumors carry a specific enzyme identified through an FDA-approved test.
The drug first earned FDA approval in 2014 to treat metastatic non-small cell lung cancer patients who did not respond to the cancer drug crizotinib.
More articles on supply chain:
Pharma spent $78M on lobbying so far this year: 4 statistics
Dr. Scott Gottlieb talks drug price strategies, FDA hiring freeze: 4 takeaways
Supply chain tip of the day: Schedule daily huddles with surgical teams
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
